10mg Cagrilintide, lyophilized, in a 3mL sterile glass vial
Cagrilintide is a synthetic long-acting amylin analog peptide designed for research applications. This compound represents a modified version of the naturally occurring hormone amylin, engineered with structural modifications to extend its research utility and stability profile.
Scientific Background
Cagrilintide was developed as part of ongoing research into amylin analogs and their interactions with calcitonin and amylin receptors. The compound emerged from investigations into peptide modifications that could enhance stability and duration of activity in laboratory settings. Research interest in this analog stems from its structural relationship to endogenous amylin, a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells. Studies have explored its binding characteristics with RAMP/calcitonin receptor complexes in various experimental models.
Structural Information
- Peptide Classification: Long-acting amylin analog
- Molecular Formula: C₁₇₄H₂₇₉N₅₁O₅₇S₂
- Molecular Weight: Approximately 3,947 Da
- Structural Modifications: Contains specific amino acid substitutions and an acylation modification designed to extend half-life in research applications
Disclaimer Section
This information is provided for educational and research purposes only. Cagrilintide is a research compound not approved for human use. These statements have not been evaluated by the FDA or any regulatory authority. This compound is not intended to diagnose, treat, cure, or prevent any disease or medical condition.
Research use of this compound should only be conducted by qualified professionals in appropriate laboratory settings with proper institutional oversight and in compliance with all applicable regulations. Not for human consumption or clinical use.
The information presented reflects current scientific literature available for educational review and does not constitute medical advice or therapeutic recommendations.